Johnson & JohnsonJNJ
Close of Friday, October 23, 2026 · Johnson & Johnson is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$263.80
vs its Pivot
+7.5%
OnlyAlpha Score
59
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| -2.5% | +29.5% | +39.8% | +23.4% | +13.5% |
Dividend: $5.28 a share over the last 12 months, a 2.00% yield at today's price. A Dividend Aristocrat.
Who runs and owns it
In these funds
Big investors that own it (latest 13F)
| Wellcome Trust | 4.5% of holdings |
| New York State Common | 0.9% of holdings |
| Norway (Norges Bank) | 0.8% of holdings |
| Canada Pension Plan | 0.7% of holdings |
| CalPERS | 0.7% of holdings |
| Bridgewater Associates | 0.7% of holdings |
Suppliers, customers and partners
Sells to JNJ
| Gilead Sciences | Symtuza revenue share |
| Royalty Pharma | Tremfya, $178M |
| Halozyme | ENHANZE license |
| Genmab | DARZALEX royalties 12-20% ($2,443M, ~66% of rev) |
From the companies' own annual reports filed with the SEC.
Healthcare · Pharma
Get JNJ in your free daily emailAfter every close: whether JNJ is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track JNJ free → Full Stock check
Track JNJ free → Full Stock check